[Skip to Content]
[Skip to Content Landing]
Review
December 2016

Economic Evaluation of Quality Improvement Interventions for Bloodstream Infections Related to Central CathetersA Systematic Review

Author Affiliations
  • 1Cedars-Sinai Medical Center, Los Angeles, California
  • 2RAND Corporation, Santa Monica, California
  • 3College of Science, Virginia Tech, Blacksburg, Virginia
  • 4Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles
  • 5VA Greater Los Angeles Healthcare System, Los Angeles, California
JAMA Intern Med. 2016;176(12):1843-1854. doi:10.1001/jamainternmed.2016.6610
Key Points

Question  Are quality improvement interventions designed to prevent bloodstream infections related to central catheters associated with lower infection rates as well as net savings to hospitals?

Findings  In this systematic review based on data from 113 hospitals, on average, bloodstream infections declined by more than half and hospitals achieved net savings of $1.85 million over 3 years. Larger investments in the interventions were associated with greater net savings, and infections and costs declined even when checklists were already in use, and when baseline infection rates were as low as 1.7 to 3.7 per 1000 catheter-days.

Meaning  Interventions that prevent bloodstream infections can be of high value to hospitals even after infections have started to decline.

Abstract

Importance  Although quality improvement (QI) interventions can reduce central–line-associated bloodstream infections (CLABSI) and catheter-related bloodstream infections (CRBSI), their economic value is uncertain.

Objective  To systematically review economic evaluations of QI interventions designed to prevent CLABSI and/or CRBSI in acute care hospitals.

Evidence Review  A search of Ovid MEDLINE, Econlit, Centre for Reviews & Dissemination, New York Academy of Medicine's Grey Literature Report, Worldcat, prior systematic reviews (January 2004 to July 2016), and IDWeek conference abstracts (2013-2016), was conducted from 2013 to 2016. We included English-language studies of any design that evaluated organizational or structural changes to prevent CLABSI or CRBSI, and reported program and infection-related costs. Dual reviewers assessed study design, effectiveness, costs, and study quality. For each eligible study, we performed a cost-consequences analysis from the hospital perspective, estimating the incidence rate ratio (IRR) and incremental net savings. Unadjusted weighted regression analyses tested predictors of these measures, weighted by catheter-days per study per year.

Findings  Of 505 articles, 15 unique studies were eligible, together representing data from 113 hospitals. Thirteen studies compared Agency for Healthcare Research and Quality–recommended practices with usual care, including 7 testing insertion checklists. Eleven studies were based on uncontrolled before-after designs, 1 on a randomized controlled trial, 1 on a time-series analysis, and 2 on modeled estimates. Overall, the weighted mean IRR was 0.43 (95% CI, 0.35-0.51) and incremental net savings were $1.85 million (95% CI, $1.30 million to $2.40 million) per hospital over 3 years (2015 US dollars). Each $100 000-increase in program cost was associated with $315 000 greater savings (95% CI, $166 000-$464 000; P < .001). Infections and net costs declined when hospitals already used checklists or had baseline infection rates of 1.7 to 3.7 per 1000 catheter-days. Study quality was not associated with effectiveness or costs.

Conclusions and Relevance  Interventions related to central venous catheters were, on average, associated with 57% fewer bloodstream infections and substantial savings to hospitals. Larger initial investments may be associated with greater savings. Although checklists are now widely used and infections have started to decline, additional improvements and savings can occur at hospitals that have not yet attained very low infection rates.

×